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1  |  INTRODUCTION
Pre‐eclampsia affects 2%‐8% of all pregnancies and is as-
sociated with maternal, foetal and neonatal morbidity and 
mortality.1 For more than 30 years, we have known that cy-
clooxygenase (COX) inhibition with aspirin can prevent the 
onset of pre‐eclampsia. Presently, more than 45 randomized, 
controlled trials (RCTs) involving 30 000 patients have in-
vestigated the efficacy of selective COX‐1 inhibition with 
low‐dose aspirin for the prevention of pre‐eclampsia.2 While 
this preventative strategy is now generally accepted in clini-
cal practice, the risk reduction is modest and the optimal dose 
Received: 8 June 2019 | Accepted: 11 August 2019
DOI: 10.1111/bcpt.13308  
M I N I R E V I E W
Aspirin for the prevention and treatment of pre‐eclampsia: A 
matter of COX‐1 and/or COX‐2 inhibition?
Katrina M. Mirabito Colafella1,2,3 |   Rugina I. Neuman3,4 |   Willy Visser3,4 |    
A. H. Jan Danser3 |   Jorie Versmissen3
1Cardiovascular Disease Program, Monash 
Biomedicine Discovery Institute, Monash 
University, Melbourne, Vic, Australia
2Department of Physiology, Monash 
University, Melbourne, Vic, Australia
3Division of Pharmacology and Vascular 
Medicine, Department of Internal 
Medicine, Erasmus MC, University Medical 
Center, Rotterdam, The Netherlands
4Division of Obstetrics and Perinatal 
Medicine, Department of Obstetrics and 
Gynecology, Erasmus MC, University 
Medical Center, Rotterdam, The 
Netherlands
Correspondence
Katrina M. Mirabito Colafella, Department 
of Physiology, Monash University, 26 
Innovation Walk, Vic., 3800 Australia.
Email: katrina.mirabito@monash.edu
Funding information
KMMC was supported by a National 
Health and Medical Research Council 
(NHMRC) of Australia CJ Martin Early 
Career Fellowship (GNT1112125). AHJD 
and RIN were supported by a grant from the 
foundation Lijf en Leven.
Abstract
Since the 1970s, we have known that aspirin can reduce the risk of pre‐eclampsia. 
However, the underlying mechanisms explaining this risk reduction are poorly un-
derstood. Both cyclooxygenase (COX)‐1‐ and COX‐2‐dependent effects might be 
involved. As a consequence of this knowledge hiatus, the optimal dose and timing 
of initiation of aspirin therapy are not clear. Here, we review how (COX‐1 versus 
COX‐2 inhibition) and when (prevention versus treatment) aspirin therapy may in-
terfere with the mechanisms implicated in the pathogenesis of pre‐eclampsia. The 
available evidence suggests that both COX‐1‐ and COX‐2‐dependent effects play 
important roles in the early stage of aberrant placental development and in the next 
phase leading to the clinical syndrome of pre‐eclampsia. Collectively, these data 
suggest that high‐dose (dual COX inhibition) aspirin may be superior to standard 
low‐dose (selective COX‐1 inhibition) aspirin for the prevention and also treatment 
of pre‐eclampsia. Therefore, we conclude that more functional and biochemical tests 
are needed to unravel the contribution of prostanoids in the mechanisms implicated 
in the pathogenesis of pre‐eclampsia and the potential of dual COX and/or selective 
COX‐2 inhibition for the prevention and treatment of pre‐eclampsia. This informa-
tion is vital if we are to deduce the suitability, optimal timing and dose of aspirin and/
or a specific COX‐2 inhibitor (most likely using modified forms that do not cross the 
placenta) that can then be tested in a randomized, controlled trial instead of the cur-
rent practice of empirical dosing regimens.
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and timing of initiation of aspirin therapy are ongoing areas 
of debate. These controversies may, at least in part, be due 
to differences in the contribution of COX‐1 and COX‐2 to 
the pathophysiology of pre‐eclampsia which remains poorly 
understood. Here, we review how (COX‐1 versus COX‐2 in-
hibition) and when (prevention versus treatment) aspirin may 
interfere with the mechanisms implicated in the pathogen-
esis of pre‐eclampsia. The available evidence suggests that 
high‐dose (dual COX inhibition) aspirin may be superior to 
standard low‐dose (selective COX‐1 inhibition) aspirin for 
the prevention and also treatment of pre‐eclampsia.
2 |  THE PROSTANOID 
BIOSYNTHESIS PATHWAY
COX is essential for prostanoid biosynthesis (Figure 1). In 
this pathway, arachidonic acid is sequentially metabolized by 
COX into the short‐lived intermediates prostaglandin (PG) 
G2 and PGH2. Once formed, PGH2 is rapidly converted into 
thromboxane (TXA2), prostacyclin (PGI2) and other PGs 
(PGE2, PGD2 and PGF2α) via TXA2 synthase, PGI2 synthase 
and specific isomerases, respectively. TXA2 is produced pri-
marily by platelets and induces vasoconstriction, vascular re-
modelling, platelet aggregation and adhesion. PGI2, which is 
released from vascular endothelial cells, induces vasodilation 
and inhibits vascular remodelling, platelet aggregation and 
adhesion, thereby counterbalancing the effects of TXA2. 
PGs modulate vascular tone, inflammation and platelet ag-
gregation. PGD2 inhibits platelet aggregation and induces 
vasodilation and (via thromboxane receptor (TP) activation) 
vasoconstriction. Both PGE2 and PGF2α contribute to the reg-
ulation of blood pressure via their effects on vascular tone and 
renal function. Additionally, PGF2α and 8‐iso‐PGF2α, a major 
isoprostane generated through the non‐enzymatic peroxida-
tion of arachidonic acid, are markers of oxidative stress.3
There are two COX isoforms: COX‐1 and COX‐2. 
Constitutive COX‐1 is ubiquitously expressed and generates 
the majority of prostanoids during physiological situations.4 
Conversely, expression of constitutive COX‐2 is low and 
mainly restricted to the brain, thymus, gut, kidney and pla-
centa.4 Inflammatory mediators (eg, nuclear factor‐κB (NF‐
κB),5 hyperosmolality,6 endothelin (ET)‐17 and hypoxia8) 
are key drivers for an up‐regulation in inducible COX‐2. The 
affinity of aspirin is 10‐100 times higher for COX‐1 than 
COX‐2. When administered at low doses (75‐100 mg/d), as-
pirin will only bind to COX‐1 in platelets. Because of the 
irreversible action of aspirin (ie, acetylation), its inhibitory 
effects on COX‐1 and TXA2 production last for the life‐time 
of the platelet, which is approximately 1  week for mature 
platelets. Consequently, low‐dose aspirin rapidly tips the 
PGI2/TXA2 balance in favour of PGI2, but has no impact on 
PGI2 production. High‐dose aspirin (>325  mg/d) inhibits 
both COX‐1‐ and COX‐2‐dependent prostanoid generation.3
3 |  PATHOPHYSIOLOGY OF PRE‐
ECLAMPSIA
Pre‐eclampsia is defined as de novo hypertension after 
20 weeks’ gestation with new‐onset proteinuria and/or mater-
nal renal insufficiency, increased liver enzymes, neurological 
complications, haematological complications and/or utero-
placental dysfunction.9 Early‐onset pre‐eclampsia tends to 
develop before 34 weeks’ gestation, whereas late‐onset pre‐
eclampsia occurs at or after 34 weeks’ gestation. The placenta 
is thought to play a key role in the pathophysiology of both 
early‐ and late‐onset pre‐eclampsia since delivery of the pla-
centa resolves the clinical manifestation of pre‐eclampsia. The 
prevailing theory is that failure of the placental vasculature 
to adequately develop, due to impaired trophoblast invasion 
and spiral artery remodelling, leads to reduced uteroplacental 
perfusion and episodes of hypoxia/reperfusion.1 This placental 
dysfunction results in the generation and release of reactive 
oxygen species (ROS), cytokines, lipid peroxidases, ET‐1 and 
soluble Fms‐like tyrosine kinase‐1 (sFlt‐1), a naturally occur-
ring antagonist of vascular endothelial growth factor (VEGF), 
which all contribute to the clinical manifestation of pre‐eclamp-
sia. It is well‐established that the production of prostanoids is 
F I G U R E  1  Aspirin and the prostanoid biosynthesis pathway. 
Abbreviations: COX, cyclooxygenase; NF‐κB, nuclear factor‐κB; 
NSAIDs, non‐steroidal anti‐inflammatory drugs; PGD2, prostaglandin 
D2; PGE2, prostaglandin E2; PGF2α, prostaglandin F2α; PGH2, 
prostaglandin H2; PGI2, prostacyclin; PLA2, phospholipase A2; TXA2, 
thromboxane. *Depending on the receptor stimulated
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altered during pre‐eclampsia such that the PGI2/TXA2 ratio is 
reduced3,10,11 and PGF2α and PGE2 levels are increased.12-14 
Accumulating evidence suggests that both COX‐1‐ and 
COX‐2‐dependent prostanoids contribute to the activation, ei-
ther upstream or downstream, of the pathways implicated in 
the pathogenesis of pre‐eclampsia. Consequently, both low‐ 
and high‐dose aspirin may be efficacious for the prevention 
and also treatment of pre‐eclampsia (Figure 2).
4 |  ASPIRIN FOR THE 
PREVENTION OF PRE‐ECLAMPSIA
The first case report describing the use of aspirin for the 
treatment of recurrent toxaemia of pregnancy used high‐
dose aspirin (600  mg) three times daily.15 Thereafter, an 
observational study reported a lower prevalence of pre‐ec-
lampsia in women who used aspirin during pregnancy, pre-
sumably as an analgesic meaning higher doses.16 However, 
all RCTs investigating prophylactic use of aspirin in women 
at high risk of pre‐eclampsia have used low‐dose aspirin 
(50‐160 mg/d). Meta‐analyses of these RCTs demonstrate a 
lower prevalence of pre‐eclampsia when aspirin therapy is 
initiated ≤16  weeks’ gestation particularly for early‐onset 
pre‐eclampsia.2,17,18 Accordingly, clinical guidelines recom-
mend that aspirin therapy is initiated ≤16 weeks’ gestation 
in women at high risk for pre‐eclampsia.9,19 Observational 
and prospective cohort studies suggest that 60‐80  mg/d of 
aspirin may be suboptimal and that doses of 100‐160 mg/d 
may be more efficacious for the prevention of pre‐eclamp-
sia.20-22 Consistent with these studies, a recent meta‐analysis 
of RCTs demonstrated that the relationship between aspirin 
(50‐150 mg/d) and the prevention of pre‐eclampsia is dose‐
dependent when started ≤16  weeks’ gestation,2 suggesting 
that higher doses of aspirin are superior for the prevention of 
pre‐eclampsia.
The main rationale for using low‐dose aspirin for the preven-
tion of pre‐eclampsia is to restore the PGI2/TXA2 ratio. In con-
trast to uncomplicated pregnancies where the normal increase in 
platelet TXA2 (due to pregnancy being a hypercoagulable state) 
is offset by an increase in PGI2,23,24 circulating, urinary and 
placental levels of PGI2 drop sharply during pre‐eclampsia.10,11 
F I G U R E  2  Proposed mechanisms by which COX‐1 and COX‐2 contribute to the pathogenesis of pre‐eclampsia and the ability of low 
and high dose to prevent these effects. The generation of thromboxane A2 is mediated via COX‐1 (blue). Both low‐ and high‐dose aspirin inhibit 
COX‐1, thereby improving the thromboxane A2/prostacyclin balance in favour of prostacyclin during pre‐eclampsia. COX‐2 (red) is implicated 
in the enhanced sensitivity to angiotensin II, activation of the immune system and increased oxidative stress during pre‐eclampsia. Consequently, 
COX‐2 inhibition with high‐dose aspirin may attenuate these effects. Both COX isoforms (purple) are implicated in the vascular dysfunction and 
angiogenic imbalance that occurs during pre‐eclampsia. Therefore, high‐dose aspirin may be the best option to restore the angiogenic balance and 
improve vascular function during pre‐eclampsia. AT1‐AA, angiotensin II type I receptor autoantibodies; COX, cyclooxygenase; NO, nitric oxide; 
PlGF, placental growth factor; RAAS, renin‐angiotensin‐aldosterone system; ROS, reactive oxygen species; sFlt‐1, soluble Fms‐like tyrosine 
kinase; VEGF, vascular endothelial growth factor
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Consequently, the PGI2/TXA2 ratio is skewed towards TXA2 
during pre‐eclampsia.3 This shift towards vasoconstriction is 
potentiated by altered PGF2α and PGE2 production.12-14 Since 
the reduction in PGI2 precedes the clinical onset of pre‐eclamp-
sia11 and the severity of pre‐eclampsia is positively correlated 
with TXA2,25 alterations in vasodilator/vasoconstrictor prosta-
noid balance seem to play a major role in the pathogenesis of 
pre‐eclampsia. Within the placenta, both COX‐1 and COX‐2 
are expressed in the villi.26-28 TXA2 is primarily produced by 
trophoblast cells near the maternal circulation, whereas PGI2 
is produced by endothelial cells near the foetal circulation.26,29 
During pre‐eclampsia, in vitro studies have demonstrated an in-
crease in trophoblast TXA2 production,29,30 which may contrib-
ute to the rise in TXA2 in the maternal circulation. Moreover, 
COX‐2 expression and activity are also increased in trophoblast 
cells from pre‐eclamptic placentas, an effect that was associated 
with increased TXA2 and PGE2 production.31 Placental up‐reg-
ulation of key drivers of inducible COX‐2 including hypoxia 
and inflammatory mediators likely contributes to the shift to-
wards vasoconstrictor prostanoids during pre‐eclampsia.8,32,33 
Additionally, prostanoids might also alter their effect on vas-
cular contractility during pre‐eclampsia. For example, vascular 
relaxation to PGI2 is associated with smooth muscle cell hyper-
polarization, such that PGI2 acts as an endothelium‐derived hy-
perpolarizing factor (EDHF).34 However, during pathological 
situations such as hypertension, obesity and diabetes, PGI2 can 
elicit vasoconstriction via stimulation of smooth muscle cell 
TPs, thereby acting as an endothelium‐derived contracting fac-
tor (EDCF).34-37 All prostanoids are able to bind to TPs, albeit 
with varying affinities, and PGI2 is the most important prosta-
noid involved in this constrictor response. However, it should 
be noted that this phenomenon is typically seen with very high 
agonist concentrations and in an ex vivo setting.35,36 TXA2, 
PGE2 and PGF2a may also contribute to endothelium‐depen-
dent contractions.34 In recent years, multiple pathways have 
been identified in the pathogenesis of pre‐eclampsia which may 
act in concert with prostanoids to promote the development of 
pre‐eclampsia. Since majority of these mechanisms are impli-
cated in the genesis of pre‐eclampsia in early pregnancy, this 
may explain why the efficacy of aspirin for the prevention of 
pre‐eclampsia is greater when initiated ≤16 weeks’ gestation. 
Moreover, consistent with a dose‐dependent relationship exist-
ing between aspirin and pre‐eclampsia, accumulating evidence 
suggests a greater contribution of COX‐2 than COX‐1 in the 
mechanisms implicated in the pathogenesis of pre‐eclampsia.
4.1 | Initiating aspirin therapy in early 
pregnancy (≤16 weeks’ gestation)
4.1.1 | VEGF inactivation
VEGF, which is integral to placental vasculogenesis and 
angiogenesis, increases progressively during uncomplicated 
pregnancies.38 During pre‐eclampsia, VEGF is reduced in 
association with increased (placental) production of sFlt‐1. 
This increase in sFlt‐1 is evident weeks before the clinical 
onset of pre‐eclampsia, suggesting a key role for VEGF in-
activation in the pathogenesis of pre‐eclampsia. Likewise, 
artificial increases in sFlt‐1 induce hypertension, renal injury 
and proteinuria in pregnant rodents.39,40 Of interest, cancer 
patients and animals treated with VEGF inhibitors (VEGFi), 
which function in much the same way as sFlt‐1, exhibit a 
pre‐eclampsia‐like syndrome characterized by hypertension 
and kidney damage.41 In mice, VEGFi induces an up‐regula-
tion of COX‐2 and PGE2, at least in tumour tissue.42 In line 
with this, sFlt‐1‐induced hypertension in mice is abolished 
by high‐dose aspirin or picotamide, a TXA2 synthase and 
TP antagonist,43 suggesting that prostanoids may contribute 
to the hypertension and renal injury during VEGF inactiva-
tion. Similarly, in BPH/5 mice which spontaneously develop 
the hallmarks of pre‐eclampsia, decidual COX‐2 inhibition 
diminishes pregnancy‐induced hypertension and improves 
foetal outcome.44 Interestingly, Li et al45 recently demon-
strated that aspirin and the specific COX‐1 inhibitor, sc‐560, 
can inhibit the expression and release of sFlt‐1 in primary 
cytotrophoblasts cultured from pre‐eclamptic placentas. 
Consistent with these findings, Murtoniemi et al46 reported 
an association between low‐dose aspirin started <14 weeks’ 
gestation and higher longitudinal increase in serum placental 
growth factor (PlGF) concentration in women at high risk 
of pre‐eclampsia. As PlGF is homologous to VEGF and 
similarly acts as a natural ligand of sFlt‐1, the up‐regulation 
of PlGF during low‐dose aspirin therapy may be indirectly 
through sFlt‐1 inhibition. Unfortunately, other trials report-
ing that aspirin prevents pre‐eclampsia have not investigated 
the effect of aspirin on angiogenic markers such as VEGF 
or sFlt‐1. Nevertheless, since VEGF contributes to placental 
vasculogenesis which is completed in the first trimester, an 
inhibitory effect of aspirin on sFlt‐1 may underlie the long‐
held belief that commencing aspirin therapy <13 weeks’ ges-
tation facilitates placentation.47
4.1.2 | Dysregulation of the nitric oxide 
(NO) pathway
NO deficiency, due to (a) decreases in NO‐dependent vaso-
dilators (eg oestrogen and VEGF) or increases in sFlt‐1 and 
inflammatory mediators, or (b) reduced bioavailability of NO 
secondary to increased oxidative stress, contributes to the 
pathogenesis of pre‐eclampsia and maternal endothelial dys-
function.48,49 NO can stimulate or suppress the COX pathway 
depending on basal NO release, the cell type in which pros-
tanoid biosynthesis occurs and the intensity of the stimulus for 
prostanoid generation.50 Decreased NO bioavailability may 
lead to a compensatory increase in endothelial PGI2 to induce 
vasodilation and endothelium‐dependent hyperpolarization,3 
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while ROS generation potentiates EDCF‐mediated responses 
by reducing NO and increasing vasoconstrictor prostanoid 
generation.34 The coupling product of NO and superoxide 
is peroxynitrite which directly increases the catalytic ac-
tivity of COX‐2 and the production of PGE2 and PGD2.51 
Peroxynitrite also decreases PGI2 synthase, thereby leading 
to a reduction in PGI2, but has no effect on TXA2 synthase.3 
Consequently, oxidative stress may contribute to the shift 
in the PGI2/TXA2 ratio during pre‐eclampsia. Additionally, 
since oxidative stress increases the non‐enzymatic generation 
of isoprostanes which are endogenous ligands for TP,3 iso-
prostanes may contribute to the deleterious effects attributed 
to TXA2 during pre‐eclampsia. COX activation can alter NO 
synthesis.50 In vitro studies suggest that both PGI2 and PGE2 
induce vascular NO release from the endothelium by cyclic 
AMP (cAMP)–mediated effects.50 Conversely, aspirin has 
been suggested to be able to rescue ROS‐induced down‐regu-
lation of eNOS which may in turn alter NO production, but 
this has never been studied in human beings.52 Furthermore, 
oxidative stress generates lipid peroxidases which increase 
COX and TXA2. In women at risk of pre‐eclampsia, low‐dose 
aspirin (81 mg/d) initiated between 9 and 34 weeks’ gesta-
tion decreased lipid peroxidases and TXA2 without altering 
PGI2 (measured after 3‐4 days and 3‐4 weeks of treatment).53 
Moreover, in pre‐eclamptic placental tissue incubated with 
varying doses of aspirin, the inhibitory effect of aspirin on 
lipid peroxidases was demonstrated to be dose‐dependent.54
4.1.3 | Immunity and inflammation
The immune system is normally suppressed during pregnancy 
to prevent the rejection of the foetus. During pre‐eclampsia, 
both the innate and adaptive immune systems are activated 
55 with elevations in circulating pro‐inflammatory cytokines 
including tumour necrosis factor‐α (TNF‐α).56 Interestingly, 
both TNF‐α and IL‐1β induce PGE2 biosynthesis within the 
decidua.57 Activation of the NF‐kB pathway during pre‐ec-
lampsia, initiated by toll‐like receptors, induces the release 
of inflammatory cytokines and causes an up‐regulation of 
COX‐2.58 Aspirin can bind to the cellular kinase IKK‐β, 
thereby preventing NF‐kB‐mediated regulation of gene ex-
pression, independent of the COX‐prostanoid pathway.59 
Thus, aspirin administration could impede NF‐kB‐induced 
downstream activation of COX‐2‐ and TNF‐α‐mediated en-
dothelial dysfunction in vivo, significantly lowering hyper-
tension and proteinuria.52,58 Inflammatory cells, particularly 
macrophages which make significant amounts of NO and 
superoxide, may also contain high levels of COX as perox-
ynitrite is an important modulator of COX activity.51 In ad-
dition, aspirin can induce lipoxin production which reduces 
leucocyte adhesion in human umbilical vein endothelial cells 
exposed to pre‐eclamptic plasma.60 Hence, through differ-
ent mechanisms, both COX‐1 and COX‐2 inhibition might 
be able to dampen the aberrant inflammatory state during 
pre‐eclampsia.
4.2 | Additional effects of aspirin therapy in 
later pregnancy (>16 weeks’ gestation)
4.2.1 | Activation of the endothelin 
(ET) system
Circulating ET‐1 is increased ~1.5‐2‐fold during pre‐eclamptic 
pregnancies,61 and multiple regression analysis demonstrates 
that ET‐1 is an independent determinant of hypertension and 
proteinuria during pre‐eclampsia.62 Furthermore, circulat-
ing ET‐1 is elevated in cancer patients and animals treated 
with VEGFi,63 suggesting that activation of the ET system 
is secondary to the angiogenic imbalance occurring in early 
pregnancy. Importantly, hypertension and renal damage are 
prevented by ET receptor blockade in animal models of pre‐
eclampsia and VEGFi‐induced hypertension, demonstrating 
a key role for activation of the ET system in pre‐eclampsia.64 
In mice treated with sFlt‐1, pressor responsiveness to ET‐1 is 
enhanced in isolated carotid artery segments and this effect is 
abrogated by indomethacin, a non‐specific COX inhibitor.43 
In vitro COX‐2 expression is increased by ET‐1 in endothe-
lial cells65 and mesangial cells.66 In vivo COX‐2 expression 
is down‐regulated by dual ETA/B receptor blockade or selec-
tive ETA receptor blockade in cirrhosis‐related angiogenesis 
in rats.67 Hypoxia is also a key driver of overexpression of 
ET‐1,68 with increases in both ET‐1 and 8‐iso‐PGF2α ob-
served in both the maternal and foetal circulations in the ex 
vivo dually perfused placental perfusion model in response 
to hypoxia.69 Moreover, decreased vasodilatory endothelial 
ETB receptor expression may contribute to the decline in 
PGI2 during pre‐eclampsia.70 Collectively, these data suggest 
that the deleterious effects of activation of ET‐1 system dur-
ing pre‐eclampsia are in part mediated via prostanoids and 
that high‐dose aspirin or a selective COX‐2 inhibitor may be 
more efficacious than low‐dose aspirin for the prevention of 
these effects. Whether COX inhibitors reduce ET‐1 levels 
has not been investigated.
4.2.2 | Enhanced sensitivity to angiotensin II
The characteristic refractoriness to angiotensin II observed 
during uncomplicated pregnancies is lost during pre‐ec-
lampsia, with an enhanced pressor response to angiotensin 
II evident as early as 23 weeks’ gestation.71,72 In normoten-
sive pregnant women (≥28 weeks’ gestation), administration 
of indomethacin or high‐dose aspirin (600 mg) reduces the 
concentration of angiotensin II needed to evoke a 20 mm Hg 
rise in blood pressure,73 suggesting that prostanoids medi-
ate the reduced sensitivity to angiotensin II. Similar find-
ings are also reported in pregnant ewes, with both PGI2 and 
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PGE2 implicated in the refractoriness to angiotensin II.74,75 
Whether the shift in the vasodilator/vasoconstrictor pros-
tanoid balance or PGI2 acting as an EDCF via stimulation 
of TP during pre‐eclampsia contributes to the enhanced sen-
sitivity to angiotensin II is unknown. However, in isolated 
aortic rings from (non‐pregnant) spontaneously hypertensive 
rats, the enhanced sensitivity to angiotensin II was associated 
with the release of vasoconstrictor prostanoids.76 This effect 
was inhibited by a preferential COX‐2 inhibitor,76 suggest-
ing that COX‐2‐dependent prostanoids enhance the sensitiv-
ity to angiotensin II during pathological situations such as 
hypertension. In pre‐eclampsia, agonistic antibodies against 
the angiotensin type 1 receptor (AT1‐AA)70,77 may potenti-
ate this effect. Studies utilizing human primary trophoblasts 
and vascular smooth muscle cells and the reduced uterine 
perfusion model of pre‐eclampsia have demonstrated that 
AT1‐AA stimulate the generation of ROS, inflammatory me-
diators (NF‐kB), ET‐1 and sFlt‐1,77,78 which in turn increase 
COX‐2‐dependent prostanoid generation. Consequently, 
COX‐2 inhibition may normalize the sensitivity to angioten-
sin II during pre‐eclamptic pregnancies.
5 |  ASPIRIN FOR THE 
TREATMENT OF THE CLINICAL 
MANIFESTATION OF PRE‐
ECLAMPSIA
The clinical manifestation of pre‐eclampsia is hypertension, 
widespread endothelial damage and end‐organ damage. In 
addition to aspirin intervening in the pathogenesis of pre‐ec-
lampsia, it might have an independent effect on these clinical 
manifestations. Low‐dose aspirin may lower blood pressure, 
although a recent RCT did not confirm this.79,80 On the other 
hand, higher doses of non‐steroidal anti‐inflammatory drugs 
(NSAIDs) can cause hypertension, probably due to salt re-
tention. A similar contradiction is the case for renal effects, 
where NSAIDs, that is inhibitors of COX‐1 and/or COX‐2, 
increase the risk of acute renal insufficiency. The underlying 
mechanism is decreased PGE2 and PGI2 leading to an inabil-
ity to maintain renal blood flow. The risk is greatest in cases 
of a low circulating volume, for instance due to diuretics, or 
when using renin‐angiotensin‐aldosterone system inhibitors 
(RAASi) which prevent compensatory vasoconstriction of the 
efferent arteriole; the combination of a diuretic, RAASi and 
NSAID is known as ‘triple whammy’81 However, COX‐2 in-
hibition seems beneficial in nephropathy in normotensive or 
hypertensive individuals and might be a drug target for pro-
teinuria.82,83 During pregnancy, the increased plasma volume 
will most likely prevent the unfavourable haemodynamic ef-
fects of NSAIDs, although once pre‐eclampsia develops one 
should be careful due to potentially relative hypovolaemia.70 
A last potential way of action is the best‐known effect of 
aspirin and the mechanism underlying the use of aspirin for 
the secondary prevention of cardiovascular disease (and ear-
lier as primary prevention of cardiovascular disease though 
the risk of bleeding may outweigh the benefit84,85): irrevers-
ible inhibition of platelet COX‐1 leading to less platelet ac-
tivation and consequently thrombus formation. However, a 
recent study did not show a relationship between the effect 
on platelet function and placental outcome although this 
study may have been underpowered.22 However, this an-
tithrombotic effect may influence the risk/benefit balance 
since high‐dose aspirin could increase the risk of bleeding, 
especially gastrointestinally. This would also be an argument 
in favour of selective COX‐2 inhibition.86 Alternatively, a 
proton pump inhibitor (PPI) could be advised since PPI use 
after 28 weeks’ gestation was associated with a reduced risk 
of early‐onset pre‐eclampsia,87 although the first RCT was 
negative.88
6 |  FOETAL AND NEONATAL 
CONSIDERATIONS OF ANTENATAL 
COX INHIBITION
In mice, genetic COX‐1 deficiency is associated with de-
layed parturition and reduced offspring survival,3 whereas 
COX‐2‐deficient mice are infertile, develop nephropa-
thy and die earlier than their wild‐type counterparts.3 
Accordingly, animal studies suggest that NSAIDs induce 
teratogenicity and other adverse foetal effects.89 However, 
human data concerning adverse foetal and neonatal effects 
of NSAIDs are less conclusive.89 In the first two trimesters, 
NSAIDs seem to have limited risk. In the last trimester, 
lower prostaglandin levels increase the risk of premature 
closure of the ductus arteriosus (DA), oligohydramnios as 
well as foetal renal failure.89 Low‐dose aspirin is known 
to be safe throughout human pregnancy with no associa-
tion between its use and pregnancy (placental abruption, 
miscarriage) or foetal (congenital anomalies, neonatal in-
traventricular haemorrhage and premature closure of the 
DA) complications.18,90-92 Negative long‐term effects on the 
offspring following antenatal aspirin therapy are unlikely, 
although a recent epidemiological study from China sug-
gests that maternal aspirin use during pregnancy is associ-
ated with childhood asthma by 7 years of age.93 However, a 
positive effect of maternal aspirin use during pregnancy on 
childhood blood pressure has also been reported.94 Whether 
high‐dose aspirin or a specific COX‐2 inhibitor is safe to use 
during pregnancy requires further investigation. We know 
that COX inhibitors including aspirin and indomethacin are 
able to cross the human placental barrier.89 COX inhibitors 
including indomethacin are used in clinical practice for to-
colysis, since they provide a better combination of delayed 
delivery (for at least 48  hours and up to 7‐10  days) and 
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maternal tolerance89 than conventional tocolytics. However, 
the use of indomethacin as a tocolytic agent is limited by 
adverse foetal and neonatal effects as described above.89 In 
contrast, a recent cohort study in women with short cervix 
reported that starting indomethacin treatment earlier in preg-
nancy (initiated <25  weeks’ gestation and continued until 
delivery or 32 weeks’ gestation, whichever came first) did 
not increase foetal (oligohydramnios and DA constriction) 
or neonatal (pulmonary haemorrhage, patent DA requiring 
medical intervention, necrotizing enterocolitis, spontaneous 
intestinal perforation, intraventricular grade III‐IV or other 
intracranial haemorrhage and mortality) complications.95 
This suggests that COX‐2 inhibition may be safer during 
early pregnancy rather than later which is in line with known 
safety data for NSAIDs. To the best of our knowledge, no 
study has investigated human placental transfer of selective 
COX‐2 inhibitors (although it is expected that they are able 
to cross the placental barrier) and little is known about the 
foetal and neonatal effects of selective COX‐2 inhibitors.
7 |  PERSPECTIVES AND 
CLINICAL IMPLICATIONS
Accumulating evidence demonstrates a greater role for 
COX‐2 than COX‐1 in the pathogenesis of pre‐eclampsia, 
suggesting that high‐dose aspirin or a selective COX‐2 in-
hibitor (potentially on top of low‐dose aspirin to obtain maxi-
mum benefits of both without the deleterious gastrointestinal 
effects associated with excessive COX‐1 inhibition) may be 
more efficacious than low‐dose aspirin. More functional and 
biochemical tests are needed in preclinical and clinical stud-
ies to unravel the contribution of prostanoids in the mecha-
nisms implicated in the pathogenesis of pre‐eclampsia and 
the potential of dual COX and/or selective COX‐2 inhibition 
for the prevention and treatment of pre‐eclampsia. Positive 
findings in these studies will provide a strong rationale for 
the development of modified forms of aspirin and/or se-
lective COX‐2 inhibitors that do not to cross the placental 
barrier. These studies will give more information about the 
suitability, optimal timing and dose of aspirin and/or a spe-
cific COX‐2 inhibitor that could then be tested in an RCT 
instead of the current practice of empirical dosing regimens. 
This is vital if we are to prolong pregnancy without compro-
mising maternal or foetal health. Understanding how aspirin 
prevents pre‐eclampsia may improve lifelong cardiovascular 
health for both mother and child.
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